Abstract: The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.

Abstract: In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt % to 3 wt % ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.

Abstract: Methods of applying a solid forming local anesthetic formulations can include applying a layer of a solid-forming formulation to a skin surface, wherein the solid-forming local anesthetic formulation includes from 4 wt % to 30 wt % of a local anesthetic, less than 36 wt % dicalcium phosphate, water, and a polymer. These methods can further include maintaining the layer of the formulation on the skin surface for a period of time sufficient to allow the layer of the formulation to transition from a semi-solid to a cohesive film and to topically deliver the local anesthetic to the skin surface, and removing the layer of the formulation from the skin surface by peeling the layer of the formulation off the skin surface. The layer of the formulation can be operable to be removed as a single piece or two to three large pieces.

Abstract: Systems and methods for coupling a barrel to a firearm are disclosed, including firearms incorporating the systems. In an embodiment, the firearm includes a receiver including a cavity and an internal thread disposed within the cavity. In addition, the firearm includes a barrel including a first threaded connector that is threadably engaged with the internal thread within the cavity and a second threaded connector. Further, the firearm includes a barrel nut including an internal thread and an external thread. The internal thread of the barrel nut is threadably engaged with the second threaded connector of the barrel.

Abstract: The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.

Abstract: The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.

Abstract: Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.

Abstract: The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.

Abstract: Systems and methods for coupling a barrel to a firearm are disclosed, including firearms incorporating the systems. In an embodiment, the firearm includes a receiver including a cavity and an internal thread disposed within the cavity. In addition, the firearm includes a barrel including a first threaded connector that is threadably engaged with the internal thread within the cavity and a second threaded connector. Further, the firearm includes a barrel nut including an internal thread and an external thread. The internal thread of the barrel nut is threadably engaged with the second threaded connector of the barrel.

Abstract: Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.

Abstract: In one example presented herein, is a pharmaceutical composition. The pharmaceutical composition can include halobetasol propionate, from 0 wt % to 3 wt % ethoxylated castor oil, a first compound, and a second compound. The first compound and the second compound can be selected from; N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. The first compound and the second compound are not the same.

Abstract: Solid-forming topical formulations can include a local anesthetic, an emulsifying agent, polymer, and water. The formulation can include from 0.1 wt % to 5 wt % more of the emulsifying agent, from 0.1 wt % to 20 wt % more of the polymer, and from 0.1 wt % to 30 wt % more water than a comparative formulation, and drying time is faster than the comparative formulation when applied to a skin surface and dried under the same ambient conditions.

Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes an active agent, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a drug such as a local anesthetic, an NSAID, or a corticosteriod; and sodium lauryl sulfoacetate. The topical formulations can have enhanced physical and/or chemical stability as compared to similar formulations without sodium lauryl sulfoacetate.

Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Abstract: The present disclosure provides for an apparatus and related method for controlling the rate of nicotine delivery into systemic circulation of a subject. The method comprises transdermally administering nicotine at a topical administration site of a subject; achieving a steady state plasma concentration of nicotine in the subject; and activating a temperature modification apparatus over the topical administration site after achieving the steady state. The temperature modification apparatus can be configured to generate heat for a predetermined period of time. Further, about 5 to about 30 minutes following activation of the temperature modification apparatus, the subject's nicotine plasma concentration increases by at least about 5% over the subject's steady state nicotine plasma concentration.

Abstract: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.

Abstract: An apparatus to rapidly deliver a drug to a patient, the invention comprising the method of locating a drug beneath a patient's skin in a drug depot site, placing a heating component near the drug depot site and generating heat in and near the drug depot site. A control component connected to the heating component is used to control the magnitude and duration of heat generated by the heating component.